MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why RAPP Stock surged +7.60% Today — RQD Quant Desk Flash
$24.21 +7.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $24.50
Rapport Therapeutics Inc. (RAPP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $1.16B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RAPP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $24.21 (+7.60% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RAPP ranks #544 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RAPP compare to VSTM and AMPH in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, VSTM (Verastem Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.17B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.15B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RAPP?
▼
Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $0 in revenue, -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $24.50 (+1.18%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RAPP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY RAPP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)
FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$30.65-10% Next Q
51
Q2 (-2Q)Grade D$27.57-5.9% Next Q
48
Q3 (-1Q)Grade D$25.93-6.6% Next Q
46
CurrentGrade D-$24.21-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RAPP Turnaround Squeeze
While RAPP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($36.70) and Max Pain ($25.42) forces dealer call-delta covering toward $55.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RAPP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RAPP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RAPP Stock surged +7.60% Today — RQD Quant Desk Flash
Rapport Therapeutics Inc. (RAPP) surged +7.60% to $24.21, trading at 7% of its 52-week range ($22.06 – $52.93). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($22.06 – $52.93) with RSI-14 at 37.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $24.21 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RAPP Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RAPP)
- ✓Walkthrough of RAPP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RAPP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.92%🛡️ HOLDING TREND SUPPORT
2026-10-30O $23.94H $25.43L $23.86C $24.21VOL 923.3K
RES: $60.11SUP: $21.85SMA50: $36.70SMA200: $35.65
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RAPP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RAPP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RAPP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RAPP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RAPP)
Health Care Rank #544 of 1016
⚔️ VSTM vs RAPP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RAPP vs. VSTM, AMPH, AVLN, SPTX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapport Therapeutics Inc. (RAPP) ranks #544 by composite RQD confidence (43/100, grade D-) and #342 by equity capitalization ($1.16B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with RAPP at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RAPP
ACTIVE
Rapport Therapeutics Inc. | D- | 43/100 | — | — | -22.9% | +7.60% | $1.16B | Benchmark Subject |
| VSTM Verastem Inc. | E | 24/100 | — | — | -35.0% | -1.78% | $1.17B | /vstm-vs-rapp → |
| AMPH Amphastar Pharmaceuticals Inc. | B- | 71/100 | 11.7x | 49.5% | 9.0% | +2.28% | $1.15B | /amph-vs-rapp → |
| AVLN Avalyn Pharma Inc. | D | 49/100 | — | — | — | -0.12% | $1.14B | /avln-vs-rapp → |
| SPTX Seaport Therapeutics Inc. | D+ | 56/100 | — | — | — | +3.53% | $1.13B | /sptx-vs-rapp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002012593In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapport Therapeutics Inc. (RAPP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$111.5M, operating cash flow of -$87.5M, and free cash flow of -$88.1M (-31.0% YoY). On the balance sheet, RAPP closed FY2025 with $512.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$111.5M | -$87.5M | -$88.1M | $512.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$78.3M | -$64.8M | -$67.2M | $314.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$34.8M | -$27.2M | -$27.2M | — | — |
3. RAPP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $24.21 (+7.60% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RAPP ranks #544 in composite RQD confidence.
How does RAPP compare to VSTM and AMPH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, VSTM (Verastem Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.17B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.15B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RAPP?
Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $0 in revenue, -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RAPP trading relative to its 50-day, 200-day, and 52-week technical levels?
RAPP last traded at $24.21 (+7.60% on volume of 3,096,941 shares), positioning the stock -34.03% below its 50-day simple moving average ($36.70) and -32.09% below its 200-day simple moving average ($35.65). Across its 52-week range of $22.06 to $52.93, RAPP sits at the 7.0% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($21.18 to $27.24).
RAPP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RAPP stock moving today?
Why RAPP Stock surged +7.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.